Subscribe

Tong Ren Tang Technologies Co. Ltd. (1666.HK)

HKD3.43 +0.07 (+2.08%)
CN HKSE Healthcare Drug Manufacturers - General
Address No. 20 Nansanhuan Zhonglu Road 100079
Beijing, CN
CEO Yi Zhang
Website tongrentangkj.com
IPO 2000-10-31
ISIN CNE100000585

Explore sections of this company profile

Also trades on Hong Kong Stock Exchange · 1666.HK (HKD) Other OTC · TGRNF (USD)
Description

Tong Ren Tang Technologies Co. Ltd., a company founded in 1669 and based in Beijing, People's Republic of China, maintains extensive operations across Mainland China and Hong Kong. Its primary activities center on the manufacturing and sale of traditional Chinese medicine products. The company's involvement is comprehensive, extending to the cultivation, sourcing, and distribution of Chinese medicinal raw materials. Beyond its core offerings, Tong Ren Tang diversifies its product portfolio with items such as ointments, tea beverages, and specialized foot care solutions. The enterprise is also active in the technological advancement and commercialization of biological products, alongside Western pharmaceuticals, cosmetics, and general healthcare goods. Its distribution network includes both wholesale and retail channels for Chinese medicines and health-related products. Furthermore, Tong Ren Tang provides a broad spectrum of services, including medical research and development, Chinese medical consultation and treatment, advertising, internal and external surgical procedures, medical examinations, and hospital management. Additionally, the company engages in the processing of biochemical products, plant extraction, and the production of various food and daily chemical items.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD3.43 +0.07 (+2.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.78
Float Shares
585.32M
Free Float %
45.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.57% -3.83% -8.33% -19.63% -25.74% -20.18% -30.84% -49.50% -54.87% -71.61% +391.16%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
3.43
DCF (Unlevered) 11.75 +242.6%
DCF (Levered) 17.54 +411.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 +1
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.33
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    -10.7% Q4'25: -2.9% (vs Q4'23)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    -24.4% Q4'25: -73.5% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +18.8% ★ Q4'25: +14.6% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +12.4% Q4'25: +8.5% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +8.5% Q4'25: +9.3% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    +0.0% Q4'25: +0.0% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    2.17× ★ Q4'25: 1.63× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.84) × ERP
WACC = 64% × Ke + 36% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 11.78 Current price: 3.43
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2008
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
1.21B
est: 1.13B (+7.6%)
1.58B
est: 1.27B (+24.3%)
1.94B
est: 1.40B (+38.5%)
2.45B
est: 1.97B (+24.1%)
2.91B
est: 2.41B (+20.9%)
3.34B
est: 2.70B (+23.7%)
4.07B
est: 4.66B (-12.7%)
4.67B
est: 5.14B (-9.2%)
5.03B
est: 6.23B (-19.3%)
5.06B
est: 5.82B (-13.1%)
4.48B
est: 4.40B (+1.8%)
4.61B
est: 5.52B (-16.6%)
5.40B
est: 6.68B (-19.2%)
5.99B
est: 6.56B (-8.7%)
6.77B
est: 6.40B (+5.9%)
7.26B
est: 6.77B (+7.2%)
6.48B
est: 7.30B (-11.1%)
7.25B
7.23B – 7.27B
-0.7% YoY
7.85B
7.84B – 7.86B
+8.3% YoY
8.54B
8.52B – 8.55B
+8.7% YoY
EBITDA
246.02M
est: 220.22M (+11.7%)
310.35M
est: 248.65M (+24.8%)
381.33M
est: 268.30M (+42.1%)
531.74M
est: 405.50M (+31.1%)
648.98M
est: 446.99M (+45.2%)
768.98M
est: 459.73M (+67.3%)
953.38M
est: 993.59M (-4.0%)
1.08B
est: 825.83M (+31.2%)
1.25B
est: 771.21M (+61.9%)
1.28B
est: 1.02B (+26.1%)
1.10B
est: 664.13M (+65.4%)
1.14B
est: 727.36M (+56.8%)
1.26B
est: 757.56M (+65.7%)
1.39B
est: 820.40M (+69.7%)
1.30B
est: 1.24B (+4.6%)
1.17B
est: 1.32B (-11.1%)
1.00B
est: 1.42B (-29.5%)
1.41B
1.41B – 1.41B
-0.7% YoY
1.53B
1.53B – 1.53B
+8.3% YoY
1.66B
1.66B – 1.66B
+8.7% YoY
EBIT
198.28M
est: 185.48M (+6.9%)
267.52M
est: 209.42M (+27.7%)
340.18M
est: 245.33M (+38.7%)
488.41M
est: 350.97M (+39.2%)
604.84M
est: 475.88M (+27.1%)
711.62M
est: 542.46M (+31.2%)
881.81M
est: 845.96M (+4.2%)
1.01B
est: 925.91M (+8.8%)
1.17B
est: 901.56M (+29.4%)
1.20B
est: 1.03B (+16.6%)
938.26M
est: 807.70M (+16.2%)
943.55M
est: 874.62M (+7.9%)
1.08B
est: 910.94M (+18.5%)
1.21B
est: 986.49M (+23.0%)
1.12B
est: 1.06B (+5.5%)
985.16M
est: 1.12B (-12.0%)
802.14M
est: 1.21B (-33.5%)
1.20B
1.20B – 1.20B
-0.7% YoY
1.30B
1.30B – 1.30B
+8.3% YoY
1.41B
1.41B – 1.41B
+8.7% YoY
Net Income
160.53M
est: 154.15M (+4.1%)
198.34M
est: 174.04M (+14.0%)
254.69M
est: 185.19M (+37.5%)
330.17M
est: 356.56M (-7.4%)
390.09M
est: 326.75M (+19.4%)
462.19M
est: 348.91M (+32.5%)
540.48M
est: 642.02M (-15.8%)
595.65M
est: 568.09M (+4.9%)
666.67M
est: 533.74M (+24.9%)
677.82M
est: 774.09M (-12.4%)
417.65M
est: 459.66M (-9.1%)
467.55M
est: 397.85M (+17.5%)
507.25M
est: 414.37M (+22.4%)
582.89M
est: 632.72M (-7.9%)
590.19M
est: 605.36M (-2.5%)
521.80M
est: 393.81M (+32.5%)
396.28M
est: 524.90M (-24.5%)
471.98M
470.75M – 473.21M
-10.1% YoY
531.81M
530.42M – 533.19M
+12.7% YoY
598.29M
596.74M – 599.84M
+12.5% YoY
SGA
342.34M
est: 312.41M (+9.6%)
499.18M
est: 352.73M (+41.5%)
587.08M
est: 466.19M (+25.9%)
754.61M
est: 677.30M (+11.4%)
826.38M
est: 746.73M (+10.7%)
903.59M
est: 728.32M (+24.1%)
1.13B
est: 1.13B (+0.3%)
1.36B
est: 1.16B (+16.8%)
1.36B
est: 1.19B (+13.9%)
1.23B
est: 1.41B (-12.6%)
1.12B
est: 812.25M (+37.4%)
1.10B
est: 1.04B (+5.7%)
1.21B
est: 1.09B (+11.6%)
1.39B
est: 1.18B (+18.3%)
1.71B
est: 1.56B (+10.0%)
1.89B
est: 1.65B (+14.7%)
1.60B
est: 1.78B (-9.7%)
1.77B
1.76B – 1.77B
-0.7% YoY
1.91B
1.91B – 1.92B
+8.3% YoY
2.08B
2.08B – 2.08B
+8.7% YoY
EPS
0.14
est: 0.14 (+0.1%)
0.17
est: 0.18 (-7.6%)
0.22
est: 0.21 (+2.6%)
0.28
est: 0.28 (-0.5%)
0.32
est: 0.35 (-9.8%)
0.36
est: 0.37 (-1.9%)
0.42
est: 0.50 (-16.2%)
0.47
est: 0.55 (-14.9%)
0.52
est: 0.58 (-10.7%)
0.53
est: 0.60 (-12.3%)
0.33
est: 0.49 (-32.5%)
0.37
est: 0.39 (-5.4%)
0.40
est: 0.50 (-20.5%)
0.46
est: 0.52 (-11.7%)
0.46
est: 0.47 (-2.7%)
0.41
est: 0.43 (-4.6%)
0.31
est: 0.41 (-24.4%)
0.37
0.37 – 0.37
-10.1% YoY
0.42
0.41 – 0.42
+12.7% YoY
0.47
0.47 – 0.47
+12.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-28 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-27 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-26 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-22 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-21 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-20 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-19 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-18 B+ 3/5 4/5 3/5 4/5 2/5 2/5 4/5
2026-05-15 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-14 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-05-13 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-12 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-11 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-08 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-07 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-06 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-05 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-05-04 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-04-30 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-04-29 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-04-28 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-04-27 A- 4/5 4/5 3/5 4/5 2/5 3/5 5/5
2026-04-24 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-23 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-22 B+ 3/5 4/5 3/5 4/5 1/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 1/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
2.60B
OE per share TTM
2.03
Owner's Yield
57.69%
Maintenance CapEx ratio
185.04%
Maint CapEx / Avg PPE
54.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 59 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI China Small-Cap ETF ECNS 0.14% 93.8K 0.59%
2 WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L 0.04% 17.8K 0.54%
3 State Street SPDR S&P Emerging Markets Small Cap ETF EWX 0.03% 213.2K 0.65%
4 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.03% 103.0K 0.72%
5 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.02% 16.3K 0.74%
6 iShares MSCI EM Small Cap UCITS ETF IEMS.L 0.02% 57.1K 0.74%
7 State Street SPDR S&P China ETF GXC 0.01% 64.1K 0.59%
8 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.01% 70.0K 0.55%
9 WisdomTree Emerging Markets SmallCap Dividend Fund DGS 0.01% 164.5K 0.58%
10 State Street SPDR S&P Emerging Asia Pacific ETF GMF 0.01% 34.0K 0.49%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
201.0K
Shares Outstanding
1.28B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jia Fu Chen General Manager 2M male
Chun You Zhang GM & Executive Director 1M male
Zhi Mei Feng Deputy General Manager 1M female
Yi Zhang Executive Chairman of the Board 990.4K male
Kai Ting Wen Executive Director 436.1K female
Wing Yee Ma Company Secretary — female
Guan Zhao Han Deputy GM, Chief Compliance Officer, General Legal Counsel & Board Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General